Faculty of Medicine, Syrian Private University, Damascus, Syrian Arab Republic.
Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic.
BMJ Open. 2023 Mar 20;13(3):e068849. doi: 10.1136/bmjopen-2022-068849.
This study aims to compare the clinical manifestations, laboratory findings, outcomes and overall survival time of patients with COVID-19 with and without comorbidities.
Retrospective design.
This study was undertaken at two hospitals in Damascus.
A total of 515 Syrian patients met the inclusion criterion, laboratory-confirmed COVID-19 infection following the Centers for Disease Control and Prevention. Exclusion criteria were suspected and probable cases that were not confirmed with a positive reverse transcription-PCR assay, and patients who self-discharged from the hospital against medical advice.
First, assess the impacts of comorbidities on COVID-19 infection in four areas (clinical manifestations, laboratory findings, severity and outcomes). Second, calculate the overall survival time for patients with COVID-19 with comorbidities.
Of 515 patients included, 316 (61.4%) were male and 347 (67.4%) had at least one coexisting chronic disease. Patients with comorbidities compared with no comorbidities were more vulnerable to poor outcomes such as severe infection (32.0% vs 9.5%, p<0.001), severe complications (34.6% vs 9.5%, p<0.001), the need for mechanical ventilation (28.8% vs 7.7%, p<0.001) and death (32.0% vs 8.3%, p<0.001). Multiple logistic regression showed that age ≥65 years old, positive smoking history, having ≥2 comorbidities and chronic obstructive pulmonary disease were risk factors linked to severe COVID-19 infection in patients with comorbidities. Overall survival time was lower among patients with comorbidities (vs no comorbidities), patients with ≥2 comorbidities (vs one comorbidity), and patients with hypertension, chronic obstructive pulmonary disease, malignancy or obesity (vs other comorbidities) (p<0.05).
This study revealed that COVID-19 infection had poor outcomes among those with comorbidities. Severe complications, mechanical ventilation usage and death were more prevalent among patients with comorbidities compared with those with no comorbidities.
本研究旨在比较合并症和无合并症 COVID-19 患者的临床表现、实验室检查结果、结局和总生存时间。
回顾性设计。
本研究在大马士革的两家医院进行。
共有 515 名叙利亚患者符合纳入标准,即经美国疾病控制与预防中心实验室确诊的 COVID-19 感染。排除标准为疑似和可能病例,未通过阳性逆转录-聚合酶链反应检测证实,以及未经医嘱擅自出院的患者。
首先,评估合并症对 COVID-19 感染在四个方面(临床表现、实验室检查结果、严重程度和结局)的影响。其次,计算合并症 COVID-19 患者的总生存时间。
在 515 例患者中,316 例(61.4%)为男性,347 例(67.4%)至少合并一种慢性疾病。与无合并症患者相比,合并症患者更容易出现不良结局,如严重感染(32.0%比 9.5%,p<0.001)、严重并发症(34.6%比 9.5%,p<0.001)、需要机械通气(28.8%比 7.7%,p<0.001)和死亡(32.0%比 8.3%,p<0.001)。多因素逻辑回归显示,年龄≥65 岁、阳性吸烟史、合并≥2 种疾病和慢性阻塞性肺疾病是合并症患者发生严重 COVID-19 感染的危险因素。与无合并症患者相比,合并症患者(与无合并症患者相比)、合并≥2 种疾病患者(与合并 1 种疾病患者相比)、合并高血压、慢性阻塞性肺疾病、恶性肿瘤或肥胖患者(与其他合并症患者相比)的总生存时间较低(p<0.05)。
本研究表明,合并症患者的 COVID-19 感染结局较差。与无合并症患者相比,合并症患者更常见严重并发症、需要机械通气和死亡。